A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.
Stay up to date on recent advances in oncology nursing and patient care.
SUD, Remote Monitoring Appears Feasible for Outpatient BiTE in MM
Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel
The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden
Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.
Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment
Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC